Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab + Chemo in Cervical Cancer
NCT06878222Phase 2Recruiting
- Sponsor
- Obstetrics and Gynecology Hospital of Fudan University
- Start
- Mar 2025
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of iparomlimab + tuvonralimab in Cervical Cancer (CC) (2 arms), sponsored by Obstetrics and Gynecology Hospital of Fudan University. Primary endpoints: Objective Response Rate at 9 weeks, Pathological Complete Response at 3 months and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06878222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06878222.